Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001183769 | SCV000320460 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2015-11-14 | criteria provided, single submitter | clinical testing | The p.I1974T variant (also known as c.5921T>C), located in coding exon 48 of the FBN1 gene, results from a T to C substitution at nucleotide position 5921. The isoleucine at codon 1974 is replaced by threonine, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6494 samples (12988 alleles) with coverage at this position. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be possibly damaging but tolerated by PolyPhen and SIFT in silico analyses, respectively. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Ce |
RCV001093333 | SCV001250260 | uncertain significance | not provided | 2019-09-01 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV001183769 | SCV001349590 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2023-01-27 | criteria provided, single submitter | clinical testing | This missense variant replaces isoleucine with threonine at codon 1974 of the FBN1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with cardiovascular disorders in the literature. This variant has been identified in 3/250880 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002487161 | SCV002789653 | uncertain significance | Ectopia lentis 1, isolated, autosomal dominant; Marfan syndrome; MASS syndrome; Stiff skin syndrome; Weill-Marchesani syndrome 2, dominant; Acromicric dysplasia; Geleophysic dysplasia 2; Progeroid and marfanoid aspect-lipodystrophy syndrome | 2021-09-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002518732 | SCV003256761 | likely benign | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2023-10-22 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000663834 | SCV004814618 | uncertain significance | Marfan syndrome | 2024-01-11 | criteria provided, single submitter | clinical testing | This missense variant replaces isoleucine with threonine at codon 1974 of the FBN1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with cardiovascular disorders in the literature. This variant has been identified in 3/250880 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Center for Medical Genetics Ghent, |
RCV000663834 | SCV000787191 | uncertain significance | Marfan syndrome | 2017-11-07 | no assertion criteria provided | clinical testing |